Sorrento Developed Socazolimab Enters Late-Stage Lung Cancer Study In China

China's regulatory authorities have signed off on Lee's Pharmaceutical Holdings Limited's Phase 3 trial evaluating socazolimab in small-cell lung cancer.

  • Lee Pharma has in-licensed socazolimab from Sorrento Therapeutics Inc (NASDAQ: SRNE) for the greater China territory.
  • The multicenter, randomized, double-blinded, parallel-group trial will combine socazolimab with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
  • The clearance is based on the results from an earlier Phase 1b trial in which socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile.
  • Patient recruitment will start in the second quarter of 2021.
  • Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform.
  • Price Action: SRNE shares are trading 3.7% higher at $9.21 in the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralChinalung cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!